centanafadine centanafadine centanafadine (inn) (former developmental code name eb-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (sndri) that began its development with euthymics bioscience after they acquired dov pharmaceutical. it was developed as a treatment for attention-deficit hyperactivity disorder (adhd) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. in 2011, euthymics bioscience spun off its development of centanafadine to a new company called neurovance. in march 2017, otsuka pharmaceutical acquired neurovance and the rights to centanafadine. as of january 2018, otsuka's pipeline indicates it is in phase iii clinical trials. centanafadinelegal statuslegal status us: investigational new drug identifiers iupac name (1r,5s)-1-naphthalen-2-yl-3-azabicyclohexane cas number924012-43-1pubchem cid16095349chemspider17253639uniid2a6t4uh9ckeggd10697 ychemical and physical dataformulac15h15nmolar mass209.292 g·mol−13d model (jsmol)interactive image smiles c1=c(c=cc2=cc=cc=c12)34c3cnc4 inchi inchi=1s/c15h15n/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16h,8-10h2/t14-,15+/m1/s1key:hkhcswpsuswgli-cabcvrresa-n centanafadine siteic50 (nm)actionref sert83 nmblocker net6 nmblocker dat38 nmblocker